~ Buy the TRIJARDY XR (empagliflozin; linagliptin; metformin hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

trijardy xr Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Trijardy Xr patents expire, and when can generic versions of Trijardy Xr launch?

Trijardy Xr is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are fifteen patents protecting this drug and one Paragraph IV challenge.

This drug has four hundred and eighty-five patent family members in forty-eight countries.

The generic ingredient in TRIJARDY XR is empagliflozin; linagliptin; metformin hydrochloride. There are twenty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the empagliflozin; linagliptin; metformin hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Trijardy Xr

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 21, 2030. This may change due to patent challenges or generic licensing.

There have been twenty-two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for trijardy xr?
What are the global sales for trijardy xr?
What is Average Wholesale Price for trijardy xr?

Summary for trijardy xr

International Patents:	485
US Patents:	15
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for trijardy xr
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for trijardy xr
What excipients (inactive ingredients) are in trijardy xr?	trijardy xr excipients list
DailyMed Link:	trijardy xr at DailyMed

Drug patent expirations by year for trijardy xr

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for trijardy xr

Generic Entry Date for trijardy xr^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up NDA: 212614 Dosage: TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for trijardy xr

Drug Class	Biguanide Dipeptidyl Peptidase 4 Inhibitor Sodium-Glucose Cotransporter 2 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors Sodium-Glucose Transporter 2 Inhibitors

Paragraph IV (Patent) Challenges for TRIJARDY XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRIJARDY XR	Extended-release Tablets	empagliflozin; linagliptin; metformin hydrochloride	5 mg/2.5 mg/1 g, 10 mg/5 mg/1 g, 12.5 mg/5 mg/1 g, 25 mg/5 mg/1 g	212614	1	2020-05-26

US Patents and Regulatory Information for trijardy xr

trijardy xr is protected by seventeen US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of trijardy xr is ⤷ Sign Up.

This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting trijardy xr

DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID

Pharmaceutical composition, methods for treating and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Pharmaceutical composition, methods for treating and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN

Pharmaceutical compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN

Pharmaceutical compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN

Pharmaceutical composition, methods for treating and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND

8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Crystalline form of 1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy- )-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Pharmaceutical composition, methods for treating and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-002	Jan 27, 2020		RX	Yes	No	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-003	Jan 27, 2020		RX	Yes	No	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-004	Jan 27, 2020		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-003	Jan 27, 2020		RX	Yes	No	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-003	Jan 27, 2020		RX	Yes	No	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-004	Jan 27, 2020		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for trijardy xr

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-002	Jan 27, 2020	⤷ Sign Up	⤷ Sign Up
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-004	Jan 27, 2020	⤷ Sign Up	⤷ Sign Up
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-001	Jan 27, 2020	⤷ Sign Up	⤷ Sign Up
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-004	Jan 27, 2020	⤷ Sign Up	⤷ Sign Up
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-003	Jan 27, 2020	⤷ Sign Up	⤷ Sign Up
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-003	Jan 27, 2020	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for trijardy xr

When does loss-of-exclusivity occur for trijardy xr?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 1175
Patent: COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE LA DIPEPTIDIL-PEPTIDASA-4 (DPP4) Y UN FARMACO ACOMPANANTE
Estimated Expiration: ⤷ Sign Up

Australia

Patent: 09232043
Patent: DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Estimated Expiration: ⤷ Sign Up

Brazil

Patent: 0911273
Patent: inibidor de dpp-iv combinado com outro agente antidiabético, comprimidos que compreendem tais formulações, seu uso e processo para sua preparação
Estimated Expiration: ⤷ Sign Up

Canada

Patent: 20450
Patent: NOUVELLES FORMULATIONS, COMPRIMES COMPRENANT DE TELLES FORMULATIONS, LEUR UTILISATION ET LEUR PROCEDE DE PREPARATION (NEW FORMULATIONS, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION)
Estimated Expiration: ⤷ Sign Up

Chile

Patent: 09000809
Patent: Composicion farmaceutica que comprende un inhibidor de la dpp4 1-[(4-metil-quinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-amino-piperidin-1-il)-xantina y metformina o sus sales, junto a l-arginina para estabilizar al inhibidor de dpp4; procedimiento de preparacion de dicha composicion.
Estimated Expiration: ⤷ Sign Up

China

Patent: 1983073
Patent: Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Estimated Expiration: ⤷ Sign Up

Patent: 3083672
Patent: DPP-IV inhibitor combined with further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Estimated Expiration: ⤷ Sign Up

Patent: 6215190
Patent: 与其它抗糖尿病药组合的DPP‑IV抑制剂、包含此类制剂的片剂，和其用途和制备方法 (Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation)
Estimated Expiration: ⤷ Sign Up

Patent: 3648422
Patent: 与其它抗糖尿病药组合的DPP-IV抑制剂、包含此类制剂的片剂，和其用途和制备方法 (DPP-IV inhibitors in combination with other anti-diabetic agents, tablets comprising such formulations, and use and processes for preparation thereof)
Estimated Expiration: ⤷ Sign Up

Colombia

Patent: 51277
Patent: INHIBIDOR DE LA DPP-IV COMBINADO CON MAS DE UN AGENTE ANTIDIABETICO, COMPRIMIDOS QUE COMPRENDEN TALES FORMULACIONES, SU USO Y PROCEDIMIENTOS PARA SU PREPARACIÓN.
Estimated Expiration: ⤷ Sign Up

Denmark

Patent: 85410
Estimated Expiration: ⤷ Sign Up

Ecuador

Patent: 10010489
Patent: Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparación
Estimated Expiration: ⤷ Sign Up

Eurasian Patent Organization

Patent: 9395
Patent: ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ ИНГИБИТОР ДПП-4 И МЕТФОРМИН, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ТВЕРДАЯ ДОЗИРОВАННАЯ ФОРМА, ВКЛЮЧАЮЩАЯ УКАЗАННУЮ КОМПОЗИЦИЮ (PHARMACEUTICAL COMPOSITION COMPRISING A DPP-4 INHIBITOR AND METFORMIN, PROCESS FOR THE PREPARATION THEREOF AND SOLID DOSAGE FORM COMPRISING SAID COMPOSITION)
Estimated Expiration: ⤷ Sign Up

Patent: 8435
Patent: ПРИМЕНЕНИЕ ФАРМАЦЕВТИЧЕСКОЙ КОМПОЗИЦИИ В ВИДЕ ТАБЛЕТКИ С ПЛЕНОЧНЫМ ПОКРЫТИЕМ ДЛЯ ЛЕЧЕНИЯ САХАРНОГО ДИАБЕТА 2 ТИПА (USE OF A PHARMACEUTICAL COMPOSITION IN THE FORM OF A FILM-COATED TABLET IN TREATING TYPE 2 DIABETES MELLITUS)
Estimated Expiration: ⤷ Sign Up

Patent: 1001577
Patent: ИНГИБИТОР ДПП-4 В КОМБИНАЦИИ С ДОПОЛНИТЕЛЬНЫМ ПРОТИВОДИАБЕТИЧЕСКИМ АГЕНТОМ, ТАБЛЕТКИ, ВКЛЮЧАЮЩИЕ УКАЗАННЫЕ КОМПОЗИЦИИ, ИХ ПРИМЕНЕНИЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
Estimated Expiration: ⤷ Sign Up

Patent: 1300121
Patent: ИНГИБИТОР ДПП-4 В КОМБИНАЦИИ С ДОПОЛНИТЕЛЬНЫМ ПРОТИВОДИАБЕТИЧЕСКИМ АГЕНТОМ, ТАБЛЕТКИ, ВКЛЮЧАЮЩИЕ УКАЗАННЫЕ КОМПОЗИЦИИ, ИХ ПРИМЕНЕНИЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
Estimated Expiration: ⤷ Sign Up

European Patent Office

Patent: 85410
Patent: DPP-IV INHIBITEUR COMBINÉ AVEC UN AUTRE AGENT ANTI-DIABÉTIQUE, COMPRIMÉS COMPRENANT LESDITES FORMULATIONS, LEUR UTILISATION ET LEUR PROCÉDÉ DE PRÉPARATION (DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION)
Estimated Expiration: ⤷ Sign Up

Patent: 53403
Patent: INHIBITEUR DPP-IV COMBINÉ À UN AUTRE AGENT ANTIDIABÉTIQUE, COMPRIMÉS COMPRENANT DE TELLES FORMULATIONS, LEUR UTILISATION ET LEUR PROCÉDÉ DE PRÉPARATION (DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION)
Estimated Expiration: ⤷ Sign Up

Patent: 44374
Patent: INHIBITEUR DE DPP-IV COMBINÉ À UN AUTRE AGENT ANTIDIABÉTIQUE, COMPRIMÉS COMPRENANT DE TELLES FORMULATIONS, LEUR UTILISATION ET LEUR PROCÉDÉ DE PRÉPARATION (DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION)
Estimated Expiration: ⤷ Sign Up

Hong Kong

Patent: 49485
Patent: DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION
Estimated Expiration: ⤷ Sign Up

Hungary

Patent: 41649
Estimated Expiration: ⤷ Sign Up

Japan

Patent: 88428
Estimated Expiration: ⤷ Sign Up

Patent: 22068
Estimated Expiration: ⤷ Sign Up

Patent: 11516456
Estimated Expiration: ⤷ Sign Up

Patent: 13237707
Patent: NEW FORMULATION, TABLET COMPRISING THE FORMULATION, THE USE AND PROCESS FOR THE PREPARATION
Estimated Expiration: ⤷ Sign Up

Mexico

Patent: 1232
Patent: INHIBIDOR DE DPP-IV COMBINADO CON OTRO AGENTE ANTIDIABETICO, TABLETAS QUE COMPRENDEN TALES FORMULACIONES, SU USO Y PROCEDIMIENTO PARA SU PREPARACION. (DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION.)
Estimated Expiration: ⤷ Sign Up

Patent: 10010819
Patent: INHIBIDORES DE DPP-IV COMBINADO CON OTRO AGENTE ANTIDIABETICO, TABLETAS QUE COMPRENDEN ESAS FORMULACIONES, SU USO Y PROCEDIMIENTO PARA SU PREPARACION. (DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION.)
Estimated Expiration: ⤷ Sign Up

Morocco

Patent: 200
Patent: صياغات جديدة، وأقراص تتكون من هذه الصيغ، استخدامها وطريقة تحضيرها
Estimated Expiration: ⤷ Sign Up

New Zealand

Patent: 7747
Patent: Combination of 1-[(methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(piperidin-1-yl)-xanthine (BI-1356), metformin and a stabilising agent
Estimated Expiration: ⤷ Sign Up

Patent: 9580
Patent: Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Estimated Expiration: ⤷ Sign Up

Peru

Patent: 091730
Patent: FORMULACIONES QUE COMPRENDEN UN INHIBIDOR DE DPP4
Estimated Expiration: ⤷ Sign Up

Patent: 140960
Patent: FORMULACIONES QUE COMPRENDEN UN INHIBIDOR DE DPP4
Estimated Expiration: ⤷ Sign Up

Poland

Patent: 85410
Estimated Expiration: ⤷ Sign Up

South Africa

Patent: 1005664
Patent: DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION
Estimated Expiration: ⤷ Sign Up

South Korea

Patent: 1611314
Estimated Expiration: ⤷ Sign Up

Patent: 1775942
Estimated Expiration: ⤷ Sign Up

Patent: 110005690
Patent: DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION
Estimated Expiration: ⤷ Sign Up

Patent: 160042174
Patent: 추가의 항당뇨병제와 병용된 ＤＰＰ-ＩＶ 억제제, 이러한 제형을 포함하는 정제, 이들의 용도 및 이들의 제조 방법 (DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION)
Estimated Expiration: ⤷ Sign Up

Patent: 170056021
Patent: 추가의 항당뇨병제와 병용된 ＤＰＰ-ＩＶ 억제제, 이러한 제형을 포함하는 정제, 이들의 용도 및 이들의 제조 방법 (- DPP-IV Inhibitor combined with a further antidiabetic agent tablets comprising such formulations their use and process for their preparation)
Estimated Expiration: ⤷ Sign Up

Spain

Patent: 96124
Estimated Expiration: ⤷ Sign Up

Taiwan

Patent: 27816
Estimated Expiration: ⤷ Sign Up

Patent: 0946534
Patent: New formulations, tablets comprising such formulations, their use and process for their preparation
Estimated Expiration: ⤷ Sign Up

Patent: 1509941
Patent: New formulations, tablets comprising such formulations, their use and process for their preparation
Estimated Expiration: ⤷ Sign Up

Tunisia

Patent: 10000431
Patent: NEW FORMULATIONS, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION
Estimated Expiration: ⤷ Sign Up

Turkey

Patent: 1818886
Estimated Expiration: ⤷ Sign Up

Ukraine

Patent: 4136
Patent: ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ВКЛЮЧАЕТ ИНГИБИТОР ДПП-4 В КОМБИНАЦИИ С ДОПОЛНИТЕЛЬНЫМ ПРОТИВОДИАБЕТИЧЕСКИМ АГЕНТОМ, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ;ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ВКЛЮЧАЄ ІНГІБІТОР ДПП-4 У КОМБІНАЦІЇ З ДОДАТКОВИМ ПРОТИДІАБЕТИЧНИМ АГЕНТОМ, ТА СПОСІБ ЇЇ ОДЕРЖАННЯ (DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION)
Estimated Expiration: ⤷ Sign Up

Uruguay

Patent: 747
Patent: NUEVAS FORMULACIONES, COMPRIMIDOS QUE COMPRENDEN TALES FORMULACIONES, SU USO Y PROCEDIMIENTO PARA SU PREPARACION
Estimated Expiration: ⤷ Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering trijardy xr around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Uruguay	28807	DERIVADOS DE BENCENO SUSTITUÍDOS POR GLUCOPIRANOSILO, MEDICAMENTOS QUE CONTIENEN ESOS COMPUESTOS, SU APLICACIÓN Y PROCEDIMIENTO PARA SU PREPARACIÓN	⤷ Sign Up
Turkey	201908974		⤷ Sign Up
China	107252430	DPP IV抑制剂的用途 (Uses of DPP-IV inhibitors)	⤷ Sign Up
South Africa	200705883	Crystalline form of 1-chloro-4-(B-D-glucopyranos-1-yl)-2-[4((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments	⤷ Sign Up
Japan	5947492		⤷ Sign Up
Ukraine	91546	КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ[КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(b-D-ГЛЮКОПИРАНОЗ-1- ИЛ)-2-[4-((S)- ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ЕЕ ПРИМЕНЕНИЕ ПРИ ПРИГОТАВЛЕНИИ ЛЕКАРСТВЕННЫХ СРЕДСТВ (CRYSTALLINE FORM OF 1-CHLORO-4-(Я-D-GLUCOPYRANOS-1-YL)-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for trijardy xr

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2187879	CA 2017 00019	Denmark	⤷ Sign Up	PRODUCT NAME: KOMBINATION AF EMPAGLIFLOZIN OG LINAGLIPTIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/16/1146/001-018 20161115
1730131	C01730131/04	Switzerland	⤷ Sign Up	PRODUCT NAME: EMPAGLIFLOZIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 63227 13.09.2021
1532149	CA 2013 00001	Denmark	⤷ Sign Up	PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3,7-DIHYDROPURIN-2,6-DION ENANTIOMERER OG SALTE DERAF - SAERLIGT LINAGLIPTIN - I KOMBINATION MED METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/12/780/001-028 20120720
1730131	PA2014035,C1730131	Lithuania	⤷ Sign Up	PRODUCT NAME: EMPAGLIFLOZINUM; REGISTRATION NO/DATE: EU/1/14/930 20140522
2187879	LUC00017	Luxembourg	⤷ Sign Up	PRODUCT NAME: GLYXAMBI- EMPAGLIFLOZINE/LINAGLIPTINE; AUTHORISATION NUMBER AND DATE: EU/1/16/1146 20161115
1532149	92128	Luxembourg	⤷ Sign Up	PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3, 7-DIHYDROPURIN-2, 6-DION, LES ENANTIOMERES ET LEURS SELS, EN PARTICULIER LA LINAGLIPTINE COMBINEE AVEC DU CHLORHYDRATE DE METFORMINE. LINAGLIPTINE
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Indicators of Generic Entry

AI Research Assistant

Questions you can ask:

Summary for trijardy xr

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for trijardy xr

Pharmacology for trijardy xr

Paragraph IV (Patent) Challenges for TRIJARDY XR

Patents protecting trijardy xr

When does loss-of-exclusivity occur for trijardy xr?

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for trijardy xr